Lascco
Company Team Projects Media Contact
 
     

An innovative therapeutic approach to bacterial infection

Combioxin develops innovative anti-virulence treatments for serious bacterial infections, including those caused by antibiotic-resistant strains. The lead candidate, CAL02, is a first-in-class, clinical-stage non-antibiotic liposomal drug that neutralizes bacterial toxins, protects against infection severity and complications, and improves antibiotic efficacy.

 

LATEST NEWS:

Independent Data Monitoring Committee concluded that CAL02 showed positive safety profile at high dose in the CAL02-001 clinical trial in pneumonia patients - 10/10/2017

Combioxin appoints industry veteran Jeffrey Jump as Chairman- 20/07/2017

Lascco